QHSLab (OTCMKTS:USAQ) and Vicarious Surgical (NYSE:RBOT) Critical Comparison

QHSLab (OTCMKTS:USAQ) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Profitability

This table compares QHSLab and Vicarious Surgical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QHSLab	15.60%	-27.74%	-6.98%
Vicarious Surgical	N/A	-184.13%	-112.50%

Analyst Ratings

This is a breakdown of recent recommendations for QHSLab and Vicarious Surgical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QHSLab	0	0	0	0	0.00
Vicarious Surgical	1	2	0	0	1.67

Vicarious Surgical has a consensus target price of $7.00, indicating a potential upside of 614.29%. Given Vicarious Surgical’s stronger consensus rating and higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than QHSLab.

Risk and Volatility

QHSLab has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Vicarious Surgical has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Insider and Institutional Ownership

47.3% of Vicarious Surgical shares are held by institutional investors. 74.2% of QHSLab shares are held by insiders. Comparatively, 9.5% of Vicarious Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares QHSLab and Vicarious Surgical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QHSLab	$2.69 million	1.94	$460,000.00	$0.03	15.46
Vicarious Surgical	N/A	N/A	-$63.22 million	($6.69)	-0.15

QHSLab has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than QHSLab, indicating that it is currently the more affordable of the two stocks.

Summary

QHSLab beats Vicarious Surgical on 8 of the 12 factors compared between the two stocks.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.

About Vicarious Surgical

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.